Siliq

Product manufactured by Bausch Health Us Llc

Application Nr Approved Date Route Status External Links
BLA761032 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Siliq ® Is Indicated For The Treatment Of Moderate To Severe Plaque Psoriasis In Adult Patients Who Are Candidates For Systemic Therapy Or Phototherapy And Have Failed To Respond Or Have Lost Response To Other Systemic Therapies. Siliq Is A Human Interleukin-17 Receptor A (Il-17ra) Antagonist Indicated For The Treatment Of Moderate To Severe Plaque Psoriasis In Adult Patients Who Are Candidates For Systemic Therapy Or Phototherapy And Have Failed To Respond Or Have Lost Response To Other Systemic Therapies. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Brodalumab

Comments